Giovanni Cordoba Solis, MD
Pulmonary Disease · Cedar Rapids, IANPI 1760903504
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 31.3% of the total.
Across 88 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$590
- GSK$299
- Regeneron Healthcare Solutions, Inc.$183
- Boehringer Ingelheim$122
- Merck$91
- Grifols USA, LLC$82
- plus $518 from 16 others
What the payments were for
- Food & beverage$1,885100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $590 |
| GSK | 23 | $299 |
| Regeneron Healthcare Solutions, Inc. | 7 | $183 |
| Boehringer Ingelheim | 5 | $122 |
| Merck | 4 | $91 |
| Grifols USA, LLC | 3 | $82 |
| Sanofi | 3 | $72 |
| Bayer | 3 | $67 |
| United Therapeutics Corporation | 3 | $67 |
| Pfizer | 2 | $45 |
| Philips North America LLC | 2 | $41 |
| 3b Medical, Inc. | 1 | $32 |
| Baxter Healthcare | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| AbbVie | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Amgen | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
How this compares
$1,885 in reported general payments places this provider in the 55th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $70,898 |
| Spiriva RespimatTiotropium Bromide | 48 | $30,653 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $29,848 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $22,152 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $21,269 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $16,316 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $13,914 |
| Arnuity ElliptaFluticasone Furoate | 39 | $12,755 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $10,131 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $9,272 |
| Spiriva HandihalerTiotropium Bromide | 14 | $8,218 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 68 | $7,745 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $7,155 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $7,121 |
| Varenicline Tartrate | 14 | $5,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $299 | $136,035278 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $122 | $60,502102 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $590 | $37,66272 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Cedar Rapids
- Syed ShahCedar Rapids$12K
- Hamad AzamCedar Rapids$9K
- Vijaya GogineniCedar Rapids$5K
- Hafiz HashmiCedar Rapids$4K
- Brian LindsayCedar Rapids$793
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.